Literature DB >> 31065911

Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents.

Marcello Tucci1, Elisa Roca2, Laura Ferrari2, Anna Pia3, Alberto Dalla Volta2, Francesca Bedussi4, Consuelo Buttigliero5, Giorgio Vittorio Scagliotti5, Sandra Sigala4, Alfredo Berruti6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31065911     DOI： 10.1007/s12020-019-01947-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

2.  Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

Authors:  Aleksi Tornio; Marja K Pasanen; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-08       Impact factor: 4.080

Review 3.  The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

Authors:  Marzia Del Re; Stefano Fogli; Lisa Derosa; Francesco Massari; Paul De Souza; Stefania Crucitta; Sergio Bracarda; Daniele Santini; Romano Danesi
Journal:  Cancer Treat Rev       Date:  2017-03-09       Impact factor: 12.111

Review 4.  Pharmacogenetic studies update in type 2 diabetes mellitus.

Authors:  Shalini Singh; Kauser Usman; Monisha Banerjee
Journal:  World J Diabetes       Date:  2016-08-10

5.  Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.

Authors:  Osman Gökalp; Arzu Gunes; Hakan Cam; Erkan Cure; Osman Aydın; Mehmet Numan Tamer; Maria Gabriella Scordo; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2011-06-21       Impact factor: 2.953

Review 6.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Authors:  Yoshihisa Shitara; Yuichi Sugiyama
Journal:  Pharmacol Ther       Date:  2006-05-22       Impact factor: 12.310

7.  Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.

Authors:  Francesca Bedussi; Diego Galli; Martina Fragni; Francesca Valcamonico; Elisa Rossini; Alberto Dalla Volta; Sara Vezzoli; Elisa Roca; Vittorio Ferrari; Barbara Lazzari; Maurizio Memo; Sandra Sigala; Alfredo Berruti
Journal:  Pharmacology       Date:  2017-08-11       Impact factor: 2.547

Review 8.  Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

Authors:  Anna Pia; Francesca Vignani; Gerhardt Attard; Marcello Tucci; Paolo Bironzo; Giorgio Scagliotti; Wiebke Arlt; Massimo Terzolo; Alfredo Berruti
Journal:  Cancer Treat Rev       Date:  2013-04-10       Impact factor: 12.111

9.  Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.

Authors:  Andrej Skerjanec; Jixian Wang; Kelly Maren; Lisa Rojkjaer
Journal:  J Clin Pharmacol       Date:  2009-11-25       Impact factor: 3.126

Review 10.  Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.

Authors:  Siew Pheng Chan; Stephen Colagiuri
Journal:  Diabetes Res Clin Pract       Date:  2015-07-09       Impact factor: 5.602
View more
  3 in total

1.  Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor.

Authors:  Yan Lu; E Wang; Ying Chen; Bing Zhou; Jiejie Zhao; Liping Xiang; Yiling Qian; Jingjing Jiang; Lin Zhao; Xuelian Xiong; Zhiqiang Lu; Duojiao Wu; Bin Liu; Jing Yan; Rong Zhang; Huijie Zhang; Cheng Hu; Xiaoying Li
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Authors:  Yi-Ting Lin; Yen-Chun Huang; Chih-Kuan Liu; Tian-Shyug Lee; Mingchih Chen; Yu-Ning Chien
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

3.  Observation of Efficacy of Internet-Based Chronic Disease Management Model Combined with Modified Therapy of Bushenyiliu Decoction in Treating Patients with Type 2 Diabetes Mellitus and Prostate Cancer and Its Effect on Disease Control Rate.

Authors:  Yi Wang; Ankang Yin; Tingting Bian; Xiangyu Zhao; Shijun Zheng; Weihua Hou; Yan Wang; Yuan Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-09       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.